Atea Pharmaceuticals, Inc.
HealthcareNASDAQ:AVIR · NASDAQ Global Select
+$0.13 today
Vol 0.19M · Avg 0.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-57.5%
avg -20.9%
ROIC
-63.0%
avg -30.4%
ROA
-50.2%
avg -24.9%
Analysis
ROA is currently the strongest return metric at -50.2% versus its period average of -24.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jean-Pierre Sommadossi | Founder, Chairman, Chief Executive Officer & President | $1.13M | — | 70 | $0.00 | <0.01% |
Janet J. Hammond | Chief Development Officer | $870,794.00 | — | 66 | $177,000.00 | 0.22% |
Andrea J. Corcoran | Chief Financial Officer, Executive Vice President of Legal & Secretary | $810,818.00 | — | 64 | $0.00 | <0.01% |
Maria Arantxa Horga | Chief Medical Officer | $747,102.00 | — | 58 | $173,500.00 | 0.22% |
John F. Vavricka | Chief Commercial Officer | $634,437.00 | — | 63 | $119,520.00 | 0.15% |
Wayne Foster | Executive Vice President of Finance & Chief Accounting Officer | $580,463.00 | — | 57 | $108,000.00 | 0.13% |
Keith Pietropaolo | Executive Vice President of Clinical Sciences & Project Management | — | — | — | — | — |
Xiao-Jian Zhou | Executive Vice President of Early Stage Development | — | — | — | — | — |
Jonae R. Barnes | Senior Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Laura Ishak | Senior Vice President of Clinical Operations | — | — | — | — | — |
Qi Huang | Senior Vice President of Virology | — | — | — | — | — |
Adel Moussa | Executive Vice President of Chemistry | — | — | — | — | — |
Jayanthi Wolf | Executive Vice President of Regulatory Affairs | — | — | — | — | — |
Nancy Gail Berry Agrawal | Executive Vice President of Preclinical Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$25,446.15
Sells
0
$0.00
Net Sentiment
+$25,446.15
Net buying
Most Active
Murphy Polly A.
1 transactions
Analysis
Insiders reported 1 buys worth $25,446.15 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $25,446.15. Murphy Polly A. was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$566.68M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$353.00M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Who manages AVIR?
Atea Pharmaceuticals, Inc. (AVIR) lists 14 active executives. The top listed executive is Maria Arantxa Horga, Chief Medical Officer.
Are AVIR insiders buying or selling?
Recent insider activity shows net buying of $81.60M.
Explore More
Continue the stock analysis
Jump to another research area for this company.